NIH director exits
This article was originally published in The Gray Sheet
Executive Summary
Elias Zerhouni will step down as director of the National Institutes of Health at the end of October, citing plans for "new opportunities, including several writing projects." Zerhouni, who was appointed to lead the 27-institute agency in 2002, is perhaps best known for two initiatives: the so-called NIH Roadmap, launched in 2003 to accelerate broad-reaching research projects that did not fit within the constructs of any single institute, and sweeping ethics reforms in 2005 that restricted NIH staffers from consulting with device and drug firms outside of formal government collaboration agreements. A trained radiologist, Zerhouni also used his stint at NIH to spotlight the benefits of medical imaging (1"The Gray Sheet" Feb. 6, 2006, p. 6)
You may also be interested in...
NIH Director Zerhouni Touts The Benefits Of Medical Imaging
In 25 years, medical imaging could eliminate the need for open surgery, according to National Institutes of Health Director Elias Zerhouni, MD
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.